Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12- month follow-up analysis Pranabashis Haldar, MD, Christopher E. Brightling, PhD, Amisha Singapuri, BSc, Beverley Hargadon, BSc, Sumit Gupta, PhD, William Monteiro, BSc, Peter Bradding, PhD, Ruth H. Green, MD, Andrew J. Wardlaw, PhD, Hector Ortega, PhD, Ian D. Pavord, DM Journal of Allergy and Clinical Immunology Volume 133, Issue 3, Pages 921-923 (March 2014) DOI: 10.1016/j.jaci.2013.11.026 Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 1 Comparison of change in inflammatory parameters, severe exacerbation rate, and clinical measures between study groups. Variable measurements presented are the group mean, with error bars representing the standard error of the mean at the time of study entry (prestudy), at the end of the treatment phase (end of study), and at sequential visits during the 12-month observation period. Blood and sputum eosinophil counts and Feno are presented as the geometric mean, with error bars representing log standard error of the mean. Feno, Fraction of exhaled nitric oxide. Journal of Allergy and Clinical Immunology 2014 133, 921-923DOI: (10.1016/j.jaci.2013.11.026) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig E1 Journal of Allergy and Clinical Immunology 2014 133, 921-923DOI: (10.1016/j.jaci.2013.11.026) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions